Valor202020212022202320242025TTMGastos comerciales, generales y administrativos743.57 M860.09 M863.75 M929.87 M995.27 M720.17 M793.27 MInvestigación y desarrollo119.75 M130.84 M153.82 M154.35 M161.67 M144.78 M163.87 MBeneficio operativo423.07 M628.1 M499.73 M506.31 M151.01 M118.37 M-219.53 MTotal de ingresos no operativos20.34 M20.62 M21.79 M-13.65 M-107.31 M28.62 M32.48 MGastos por intereses, netos de intereses capitalizados66.49 M56.97 M54.26 M85.08 M83.54 M100.22 M107.4 MIngresos no operativos, una vez deducidos los gastos por intereses-46.16 M-36.34 M-32.47 M-98.73 M-190.86 M-71.6 M-74.92 MIngresos/gastos extraordinarios———————Beneficio antes de impuestos357.73 M559.47 M445.92 M434.01 M75.48 M24.55 M-38.02 MParticipación en los beneficios———————Impuestos21.93 M74.35 M83 M76.44 M5.32 M-33.98 M-39.38 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas335.8 M485.12 M362.92 M357.57 M70.16 M58.53 M-294.68 MOperaciones suspendidas-477 K255 K223 K-1.24 M-487 K-964.17 M-714.11 MBeneficio neto335.32 M485.37 M363.14 M356.33 M69.67 M-905.64 M-1.01 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas335.32 M485.37 M363.14 M356.33 M69.67 M-905.64 M-1.01 BBeneficio básico por acción7.2110.387.747.581.49-20.3-22.8Beneficio por acción diluido7.0910.237.687.531.48-20.25-22.8Número medio de acciones ordinarias46.49 M46.77 M46.9 M46.98 M46.84 M44.62 M—Acciones diluidas47.29 M47.43 M47.31 M47.3 M47.09 M44.72 M—EBITDA427.5 M632.59 M503.78 M615.8 M659.89 M127.87 M1.28 BEBIT195.82 M390.73 M269.13 M279.8 M116.41 M-54.54 M816.99 MCosto de los ingresos1.21 B1.26 B1.26 B1.33 B1.34 B871.96 M801.57 MOtros costes de producción———————Amortización y depreciación (flujo de caja)231.68 M241.85 M234.64 M245.52 M278.02 M182.41 M465.06 M
Teleflex Incorporated Common Stock
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has annual revenues of $2.4 billion, operations in 40 countries, and more than 15,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures. Teleflex has been associated with Irish corporate tax avoidance tools. Teleflex's chief executive officer is Liam J. Kelly; Kelly is also the company's president and former chief operating officer.